Kyntra Bio reports $12 million Q2 2026 net income
Kyntra Bio reports $12 million in net income for Q2 2026, versus a $13.7 million net loss a year earlier, while FG3246, FG3180 and roxadustat programs advance.
On Thursday, Kyntra Bio (NASDAQ: KYNB ) discussed second-quarter financial results during its earnings call.
The full transcript is provided below.
APIs provide real-time access to earnings call transcripts and financial data.
Visit to learn more.
Access the full call at Summary Kyntra Bio reported a net income of $12 million for Q2 2026, a significant improvement from a net loss of $13.7 million in Q2 2025, with an increase in R&D and SG&A expenses.
The company's FG3246 and FG3180 programs in metastatic castration-resistant prostate cancer are progressing with Phase 2 trials actively enrolling; interim results are expected in Q4 2026.
Roxadustat's Phase 3 trial for anemia in lower-risk myelodysplastic syndromes is set to start in Q4 2026, with potential for strategic partnerships to further development.
Kyntra Bio maintains a cash runway into 2028, allowing continued investment in its U.S. pipeline.
Management highlighted the strategic importance of differentiating FG3246 as a non-PSMA approach and the potential competitive advantage of roxadustat in the RS-negative patient population.
Full Transcript OPERATOR (Operator) Good day and thank you for standing by.
Welcome to the Kyntra Bio second quarter 2026 earnings conference call.
At this time all participants are in a listen-only mode.
Later we will conduct a question-and-answer session.
If you would like to ask a question at that time, please press Star 11 on your telephone and wait for your name to be announced.
Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Gaia Shammas of LifeSci Advisors.
Please go ahead.
Gaia Shammas, LifeSci Advisors Thank you, Latonya, and good afternoon everyone.
Thank you for joining today to discuss Kyntra Bio's second quarter 2026 financial and business results.
I'm Gaia Shammas from LifeSci Advisors.
Joining me on today's call are Thane Weddig, Chief Executive Officer, David DeLucia, Chief Financial Officer, and Carl Gadam, Vice President of Product Development.
Following the prepared remarks, we will open the call to your questions.
I would like to remind you that remarks made on today's call include forward-looking statements about Kyntra Bio.
Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct and results of clinical trials, regulatory strategies and potential regulatory results, research and development activities, commercial results, and results of operations, risks related to our business and certain other business matters.
Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in the statement.
A more complete description of these and other material risks can be found in Kyntra Bio's filings with the SEC, including our most recent Form 10-K and Form 10-Q.
Kyntra Bio does not undertake any obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
The press release reporting the company's financial results and business updates and a webcast of today's conference call can be found on the Investors section of Kyntra Bio's website.
With that, I would like to turn the call over to the CEO, Thane Weddig.
Thane Weddig, Chief Executive Officer Thank you, Gaia.
Good afternoon everyone and welcome to our second quarter 2026 earnings call.
On today's call I will provide an update on the important progress we have made across our clinical portfolio.
First, with FG3246, our potential first-in-class antibody-drug conjugate targeting CD46 and its companion PET imaging agent in metastatic castration-resistant prostate cancer, and second, with roxadustat, our potential treatment for anemia due to lower-risk myelodysplastic syndromes.
Then David DeLucia, our CFO, will review the financials, after which we will open the call for your questions.
Starting with slide 3, I'd like to highlight our mid- and late-stage programs and upcoming catalysts.
The Phase 2 monotherapy trial for FG3246 and its companion diagnostic FG3180 in the post-ARPI, pre-chemo setting in metastatic castration-resistant prostate cancer continues to actively enroll patients, and we are on track for the results from the interim analysis in the fourth quarter of this year.